- Technology and Data
- Front End Sales and Marketing
- Allergy
- HIV
- Women's Health
- Migraine
- Compounding
- Continuous Glucose Monitoring
- Mental Health Awareness
- Veterinary Pharmacy
- CBD
- Infectious Disease
- Eye Health
- Digestive Health
- Biosimilars
- Influenza
- Shingles
- COPD Management
- Pediatrics
- Generics
- Pain Management
- COVID-19
- Immunization
- Oncology
- Anticoagulants
- Autoimmune Diseases
- Dermatology
- Diabetes
- Respiratory
- Heart Health
- Cardiovascular Clinical Consult
Trade name assigned to cold and flu treatment
Zanaflu will be the brand name for ANX-211, also known as chitosan gel, an intranasal/topical antiviral that has demonstrated efficacy against viruses responsible for the common cold, influenza, and other respiratory tract viral infections.
Zanaflu will be the brand name for ANX-211, also known as chitosan gel, an intranasal/topical antiviral that has demonstrated efficacy against viruses responsible for the common cold, influenza, and other respiratory tract viral infections. U.S. rights to the product were recently acquired from Adventrx Pharmaceuticals by TRx Pharma. The company plans to launch Zanaflu for the 2007 cold and influenza season.
To see more Hot off the Press news articles, click here.
To go to the Drug Topics homepage, click here.
Pharmacists Play Unique Role in Advancing Health Equity for Patients With Chronic Disease
December 7th 2023A new study, outlined in a poster at ASHP Midyear 2023, identified 3 key themes associated with the ways in which pharmacists are positioned to advance health equity for patients with chronic diseases.
